Panitumumab activity in metastatic colorectal cancer patients with ≥10% epidermal growth factor receptor levels

被引：0
|
作者：
Chan, E.
Neubauer, M.
Swanson, P.
Harker, W.
Burris, H.
Hecht, J.
Navale, L.
Brown, J.
Amado, R.
机构：
[1] Vanderbilt Univ Sch Med, Nashville, TN USA
[2] Kansas City Canc Ctr, Overland Pk, KS USA
[3] Hematol Oncol Associates, Port St Lucie, FL USA
[4] Utah Canc Specialists, Salt Lake City, UT USA
[5] Tennessee Oncol, Nashville, TN USA
[6] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [21] Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer
    Jean, Gary W.
    Shah, Sachin R.
    PHARMACOTHERAPY, 2008, 28 (06): : 742 - 754
  • [22] Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
    Tubb, E. E.
    Nugent, M.
    Spielberger, J.
    Axelrod, R. A.
    Mitchell, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?
    Baselga, J
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (06): : 284 - 285
  • [24] Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?
    José Baselga
    Nature Clinical Practice Oncology, 2005, 2 (6): : 284 - 285
  • [25] Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?
    Baselga, J
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (07): : C284 - C285
  • [26] INHERENT RESISTANCE IN REFRACTORY METASTATIC COLORECTAL CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES
    Galal, K.
    Zaghloul, K.
    Mourad, M. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 63 - 63
  • [27] Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
    Kendall, Anne
    Lord, Rosemary
    Maisey, Nick
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2010, 5 (02) : 142 - 151
  • [28] Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer
    Sartore-Bianchi, Andrea
    Marsoni, Silvia
    Siena, Salvatore
    JAMA ONCOLOGY, 2018, 4 (01) : 19 - 20
  • [29] Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer
    Foroughi, Siavash
    Tie, Jeanne
    Gibbs, Peter
    Burgess, Antony Wilks
    GROWTH FACTORS, 2019, 37 (5-6) : 209 - 225
  • [30] Association of gene copy number (GCN) of the epidermal growth factor receptor (EGFr) and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab monotherapy
    Berlin, J.
    Hecht, J. R.
    Reiner, M.
    Mullenix, M.
    Suggs, S.
    Radinsky, R.
    Freeman, D.
    Amado, R. G.
    Meropol, N. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 241 - 241
12345